NO972732D0 - Karsinombehandling - Google Patents

Karsinombehandling

Info

Publication number
NO972732D0
NO972732D0 NO972732A NO972732A NO972732D0 NO 972732 D0 NO972732 D0 NO 972732D0 NO 972732 A NO972732 A NO 972732A NO 972732 A NO972732 A NO 972732A NO 972732 D0 NO972732 D0 NO 972732D0
Authority
NO
Norway
Prior art keywords
karsinombehandling
carcinomas
inducer
prevention
conjunction
Prior art date
Application number
NO972732A
Other languages
English (en)
Other versions
NO318587B1 (no
NO972732L (no
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of NO972732D0 publication Critical patent/NO972732D0/no
Publication of NO972732L publication Critical patent/NO972732L/no
Publication of NO318587B1 publication Critical patent/NO318587B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19972732A 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose NO318587B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (3)

Publication Number Publication Date
NO972732D0 true NO972732D0 (no) 1997-06-13
NO972732L NO972732L (no) 1997-06-13
NO318587B1 NO318587B1 (no) 2005-04-11

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972732A NO318587B1 (no) 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose

Country Status (12)

Country Link
EP (1) EP0806963B1 (no)
JP (1) JP4076230B2 (no)
AT (1) ATE203676T1 (no)
AU (1) AU691996B2 (no)
CA (1) CA2207779C (no)
DE (1) DE69522012T2 (no)
FI (1) FI118918B (no)
GB (1) GB9425060D0 (no)
MX (1) MX9704372A (no)
NO (1) NO318587B1 (no)
NZ (1) NZ296161A (no)
WO (1) WO1996018413A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674492A (en) * 1993-12-23 1997-10-07 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
DK1974747T3 (da) * 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CA2544852A1 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1885399B1 (en) 2005-05-26 2010-10-20 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
RU2442605C2 (ru) 2005-11-01 2012-02-20 Новартис Аг Применения антител против cd40
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
CN101910414B (zh) 2007-11-07 2016-01-13 健泰科生物技术公司 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物
MX2011010938A (es) 2009-04-18 2012-01-12 Genentech Inc Metodos para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
CA2207779A1 (en) 1996-06-20
EP0806963B1 (en) 2001-08-01
MX9704372A (es) 1998-02-28
ATE203676T1 (de) 2001-08-15
DE69522012T2 (de) 2002-04-25
FI972484A (fi) 1997-06-12
CA2207779C (en) 2009-10-06
NO318587B1 (no) 2005-04-11
EP0806963A1 (en) 1997-11-19
JPH10510526A (ja) 1998-10-13
JP4076230B2 (ja) 2008-04-16
AU691996B2 (en) 1998-05-28
DE69522012D1 (de) 2001-09-06
GB9425060D0 (en) 1995-02-08
NZ296161A (en) 2001-10-26
WO1996018413A1 (en) 1996-06-20
FI118918B (fi) 2008-05-15
FI972484A0 (fi) 1997-06-12
NO972732L (no) 1997-06-13
AU3988495A (en) 1996-07-03

Similar Documents

Publication Publication Date Title
NO972732D0 (no) Karsinombehandling
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
MXPA02001726A (es) Celda de combustible y placa bipolar para utilizarse con la misma.
ATE209366T1 (de) Elektrochrome oder photoelektrochrome vorrichtung
PT935465E (pt) Compostos novos de imidazole substituido
DE3784199D1 (de) Titanocene und deren verwendung.
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
EP0492248A3 (en) Intumescent sheet, its manufacture and use
ES292314U (es) Un articulo sanitario
IT1285770B1 (it) Composti corticoidei
TW355847B (en) A surface treatment steel plate used for battery case, batterycase and battery using the case
YU45591A (sh) Novi retinoidi
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
DE69109052T2 (de) Polyolefin-Zusammensetzung und deren Verwendung.
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
NO902532L (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
FI88228C (fi) Dielektrisk resonatorkonstruktion
DE59103335D1 (de) Wassereindickende Copolymere und deren Verwendung.
ZA972776B (en) 4-[(thien-2-yl)methyl]-imidazole analgesics
TR200002939T2 (tr) Paroksetin maleat
DE69108396T2 (de) Hohe kolloidale Kapazitätsekundärbatterie, Kolloidelektrolyt und dessen Verwendung, sowie deren Herstellungsverfahren.
DE59400924D1 (de) Beta-Hydroxyoximether und bei Raumtemperatur mit beta-Hydroxyoximethern vernetzbare Dispersionen oder Lösungen
DE59106847D1 (de) Überzugsmittel sowie dessen Verwendung.
KR940018863U (ko) 온, 난방 장치를 구비한 식탁
KR900014715U (ko) 냉, 온열기의 연료절약기

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees